|
| Two Clinical Trials Now Underway Using A 2nd Generation Alpha-Prototype Instrument
These longitudinal studies are assessing patients with diabetes or age-related macular degeneration.
First Ever Metabolic Images Taken Showing Heterogeneity in Eyes with Age-Related Macular Degeneration
OcuSciences Wins
Life Sciences Sector Award
at the 2011 Accelerate Michigan Innovation Competition, |
> |
OcuSciences is commercializing a patented technology that can non-invasively detect and monitor retinal mitochondrial dysfunction.
Our technology provides the first rapid and quantitative measurement of the functional status of retinal tissue, allowing for detection of disease much earlier than currently possible.
We hope to have the technology commercially available by the end of 2012.
Please contact us at info@ocusciences.com for investment, partnership, or licensing inquiries. |
